<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="105938">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01970462</url>
  </required_header>
  <id_info>
    <org_study_id>2013H0328</org_study_id>
    <nct_id>NCT01970462</nct_id>
  </id_info>
  <brief_title>Use of Sitagliptin for Stress Hyperglycemia or Mild Diabetes Following Cardiac Surgery</brief_title>
  <official_title>Use of Sitagliptin for Stress Hyperglycemia or Mild Diabetes Following Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kathleen Dungan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled trial to determine the safety and efficacy of Sitagliptin in
      patients with stress hyperglycemia or mild diabetes following cardiac surgery.  Patients
      will receive Sitagliptin or placebo.  Sitagliptin may be of particular use in this patient
      population due to the effects on hepatic glucose production (a major feature of SH), safety
      (lack of contra-indications for heart failure or renal failure and no hypoglycemia), and
      tolerability.  The secondary objective of this study is to determine whether the management
      of patients with persistent insulin requirements following cardiac surgery differs among
      patients with stress hyperglycemia or mild diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Difference in Fasting Glucose</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <other_outcome>
    <measure>Self Monitored Blood Glucose</measure>
    <time_frame>2 and 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Adherence</measure>
    <time_frame>2 and 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Hypoglycemia</measure>
    <time_frame>2 and 6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Hyperglycemia</condition>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive Sitagliptin (renally dosed) prior to hospital discharge and 6 weeks following discharge</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive placebo prior to discharge and 6 weeks after discharge.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>Sitagliptin prior to hospital discharge and 6 weeks following discharge.</description>
    <arm_group_label>Sitagliptin</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients are reandomized to Sitagliptin or placebo for 6 weeks post-operatively</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Either of the following: Mild Diabetes Mellitus or Stress Hyperglycemia

          -  AND:

          -  Cardiac Surgery

          -  Insulin Requirement between 8-30 units subcutaneous on post-op day 3 or later off
             pressors, off enteral feeding, extubated OR glucose &gt;150 mg/dL at least twice in a 24
             hour period (&gt;4 hours apart) and otherwise not requiring basal insulin

        Exclusion Criteria:

          -  use of pressors, mechanical ventilation, or enteral or parenteral feeding within
             previous 12 hours

          -  glucocorticoids in doses exceeding the equivalent of Prednisone 10 mg/day within the
             previous 48 hours

          -  left ventricular assist device

          -  percutaneous or laparoscopic surgery

          -  end stage renal disease

          -  end stage liver disease

          -  history of pancreatitis

          -  type 1 diabetes

          -  pregnancy

          -  unable to give consent in english

          -  no phone

          -  prisoners

          -  less than 18 years of age
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen M Dungan, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kelly E Rogers, MS</last_name>
    <phone>6146886885</phone>
    <email>kelly.rogers@osumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kelly E Rogers, MS</last_name>
      <phone>614-688-6885</phone>
      <email>kelly.rogers@osumc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 27, 2013</lastchanged_date>
  <firstreceived_date>October 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Ohio State University</investigator_affiliation>
    <investigator_full_name>Kathleen Dungan</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sitagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
